| Recruiting Lags for Avandia Trial Glaxo is facing difficulties recruiting patients in the U.S. for a large clinical trial of its diabetes drug Avandia. online.wsj.com |
Problems Found at Third J&J Plant Regulators have found manufacturing problems at a third Johnson & Johnson drug-making plant. online.wsj.com |
Biotech IPO: NuPathe SA Editor Mohit Manghnani submits:NuPathe (PATH), a pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, is expected to price its IPO this week. Business Overview (from prospectus)Complete Story » seekingalpha.com |
BioClinica Responds to Shareholder Letter [Business Wire] - NEWTOWN, Pa.----BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, has issued the following statement: us.rd.yahoo.com |
Chart of the Week: Santarus Michael Kudrna submits: Santarus (SNTS) took a beating in April when it received a patent ruling loss related to its heartburn drug, ZEGERID. SNTS lost about 40% and continued a downtrend thereafter until September. On September 9th, SNTS received exclusive rights to manufacture and market CYCLOSET. This started the turnaround in the stock that has continued for over a month. SNTS has to financially recover from the loss of ZEGERID even with the appeal it made. The appeal process is likely to last at least another year or more. SNTS last reported total cash of about $99 million with debt at only $10 million so the company is in a solid position to recover.Complete Story » seekingalpha.com |